ALT
Altimmune Inc.
$2.74
-$0.06(-2.14%)
48
Overall
60
Value
45
Tech
39
Quality
Market Cap
$428.05M
Volume
4.84M
52W Range
$2.80 - $7.73
Target Price
$18.00
Company Overview
| Mkt Cap | $428.05M | Price | $2.74 |
| Volume | 4.84M | Change | -2.14% |
| P/E Ratio | -4.5 | Open | $2.78 |
| Revenue | $20.0K | Prev Close | $2.80 |
| Net Income | $-95.1M | 52W Range | $2.80 - $7.73 |
| Div Yield | N/A | Target | $18.00 |
| Overall | 48 | Value | 60 |
| Quality | 39 | Technical | 45 |
No chart data available
About Altimmune Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest News
ALT5 Sigma Announces Strategic Acquisitions with Equity Financing
TipRanks Auto-Generated Newsdesk•4 days ago
ALT5 Sigma Names Tony Isaac CEO, Approves Employment Pact
TipRanks Auto-Generated Newsdesk•4 days ago
New Buy Rating for Valterra Platinum Limited (AGPPF), the Basic Materials Giant
TipRanks Auto-Generated Intelligence Newsdesk•5 days ago
Analysts’ Top Materials Picks: Freeport-McMoRan (FCX), Alto Ingredients (ALTO)
Brian Anderson•5 days ago
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
Radhika Saraogi•5 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALT | $2.74 | -2.1% | 4.84M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |